BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3200
-0.1100 (-7.69%)
At close: 04:00PM EDT
1.3800 +0.06 (+4.55%)
After hours: 04:44PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.4300
Open1.4400
Bid1.3100 x 2200
Ask1.3900 x 800
Day's Range1.3000 - 1.4800
52 Week Range0.2510 - 1.6500
Volume418,752
Avg. Volume314,101
Market Cap103.421M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.5000
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BSGM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market

    Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform's precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation.

  • GlobeNewswire

    New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

    Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s PURE EP™ platform guidance enabled real-time tissue-specific feedback when conducting ablation Cleveland, OH and Westport, CT, May 19, 2023 (GLOBE NEWSWIRE) -- Researchers from Cleveland Clinic will be presenting data from three abstracts at Heart Rhythm 2023 that evaluated an optimized radiofrequency ablation te

  • GlobeNewswire

    BioSig to Highlight New Data from the PURE EP™ Platform at Heart Rhythm 2023

    Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP™ PlatformWestport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it will be presenting data at Heart Rhythm 2023, the Heart Rhythm Society's 44th annual meeting, on May 19-21, 2023, in

  • GlobeNewswire

    BioSig Announces New Advisory Board Member Edwin Wang

    Westport, CT, March 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of new Advisory Board member Edwin Wang. Mr. Wang has over 20 years of impactful experience in private equity, venture capital, merchant banking, and family office inves

  • GlobeNewswire

    BioSig Announces New Advisory Board Member Lorraine Spurge

    Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board. As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge began her 40-year financial career

  • GlobeNewswire

    BioSig Confirms No Exposure to Silicon Valley Bank

    Westport, CT, March 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. About BioSig TechnologiesBioSig Technologies i

  • GlobeNewswire

    BioSig Regains Compliance With All Nasdaq Listing Standards

    Westport, CT, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, announced today that it has received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the

  • GlobeNewswire

    BioSig Awarded US Patent Claims for its Universal Notch Filter Technology

    Westport, CT, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Patent can remove any fixed frequency interfering with original signal of interest preserving critical intracardiac dataBioSig now has 56 worldwide fundamental granted/allowed patents in the field of digital signal processing BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its propri

  • GlobeNewswire

    BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy

    Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly brings 15 years of public company CFO experience, including 9 years of leadership with RF chip technology giant Qorvo BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering accuracy and precision to intracardiac signal visualization with its proprietary P

  • GlobeNewswire

    BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments

    Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The Company has built a robust pipeline of commercial sale prospects and expects multiple closings in first half of 2023 New supporting clinical data to be published BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented a

  • GlobeNewswire

    BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology

    Westport, CT, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Leading Midwest healthcare system reports significant cost savings and noise reduction following evaluation of the PURE EP™ System Medical center signs agreement to acquire the Company’s digital signal processing technology for arrhythmia care BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualizati

  • GlobeNewswire

    Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore

    Abstract highlights promising results from PURE EP™ study at premier Asia-Pacific Heart Rhythm Society ConferenceWestport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that its PURE EP™ System was featured in an abstract presentation durin

  • GlobeNewswire

    BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore

    Abstract highlights promising results from PURE EP™ study at premier Asia-Pacific Heart Rhythm Society ConferenceWestport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that its PURE EP™ System was featured in an abstract presentation during

  • Simply Wall St.

    It's Unlikely That BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Will See A Huge Pay Rise This Year

    Shareholders of BioSig Technologies, Inc. ( NASDAQ:BSGM ) will have been dismayed by the negative share price return...

  • GlobeNewswire

    BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology

    Clinical abstract focuses on value of PURE EP™’s and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolationWestport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that a peer-reviewed case report titled, “Confirmatio

  • GlobeNewswire

    BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology

    Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac electrophysiology Clinical investigations conducted by Cleveland Clinic could expand clinical parameters of BioSig’s digital signal processing technology for arrhythmia care BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company deliver

  • GlobeNewswire

    BioSig Invited to Attend and Sponsor Venice Arrhythmias 2022

    Company to introduce its novel digital signal processing technology to the European EP community at world-renown international congressWestport, CT, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that it has been invited to attend the 17th Edition

  • GlobeNewswire

    BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base

    Leading medical center in San Antonio acquires BioSig’s novel digital signal processing technology for arrhythmia careWestport, CT, Oct. 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced that San Antonio Methodist Hospital has acquired the PURE EP™ System.

  • GlobeNewswire

    BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

    Company to introduce the most advanced iteration of its signal processing technology at Cleveland Clinic’s Global EP Summit 2022, a world-class leadership symposiumWestport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE E

  • GlobeNewswire

    Taglich Brothers Initiates Coverage of BioSig Technologies, Inc.

    NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces it has initiated coverage of BioSig Technologies, Inc. (NASDAQ: BSGM). BioSig Technologies, Inc., headquartered in Westport CT, is a medical technology company that is in the early stages of commercializing an FDA–cleared product, the PURE EP™ System. This system helps electrophysiologists treat patients suffering from complex arrhythmias with a procedure called cardiac catheter ablation. The complete 18-page report is

  • Zacks

    The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies

    ShockWave Medical, CheckCap and Biosig Technologies are part of The Zacks top Analyst Blog.

  • Zacks

    3 Medical Instruments Stocks With Potential to Outperform

    Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.

  • GlobeNewswire

    BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

    Westport, CT, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal pro

  • GlobeNewswire

    BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence

    Westport, CT, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Leading Medical Center of Excellence adds second PURE EP™ System for evaluation, broadening physician access to the Company’s signal processing technology PURE EP™ is now being evaluated at both Main and Fairview campuses of Cleveland Clinic’s Heart, Vascular & Thoracic Institute BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac

  • GlobeNewswire

    BioSig’s Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhythm Symposium 2022

    Leading Medical Center of Excellence Physician will discuss integrating the PURE EP™ System into their practice and procedural workflowWestport, CT, Aug. 17, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced its participation in the Kansas City Heart Rhythm Symposium, b